SCHEMBL263566

SCHEMBL263566

O=c1cc(-c2ccccc2)c(=O)c2c1c1c(=O)c3ccccc3c1n2Cc1ccccc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABCG2 Q9UNQ0 2/20 0.79
▸ CSNK2A2 P19784 1/20 0.69
▸ CSNK2B P67870 1/20 0.69
▸ CSNK2A1 P68400 1/20 0.69
▸ CDC25A P30304 3/20 0.60
▸ CDC25C P30307 3/20 0.60
▸ P2RX4 Q99571 1/20 0.43
▸ ALDH1A1 P00352 4/20 0.41
▸ MAPT P10636 4/20 0.41
▸ LMNA P02545 3/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ NTRK1 P04629 1/20 0.40
▸ RECQL P46063 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ ATM Q13315 1/20 0.39
▸ PIM1 P11309 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL263528 0.82 CSNK2A2 (1.00) ABCG2CSNK2A2CSNK2BCSNK2A1CDC25A
SCHEMBL261654 0.70 CSNK2A2 (0.76) ABCG2CSNK2A2CSNK2BCSNK2A1CDC25A
SCHEMBL21023182 0.68 P2RX4 (0.53) ABCG2CSNK2A2CSNK2BCSNK2A1P2RX4
SCHEMBL21167118 0.67 P2RX4 (0.48) ABCG2CSNK2A2CSNK2BCSNK2A1P2RX4
SCHEMBL5973866 0.63 HDAC4 (0.48) ABCG2CDC25ACDC25CALDH1A1MAPT
SCHEMBL21953164 0.62 P2RX4 (0.53) CSNK2A2CSNK2BCSNK2A1P2RX4ALDH1A1
SCHEMBL29904927 0.62 P2RX4 (1.00) P2RX4ALDH1A1MAPTSMN1; SMN2MAPK1
SCHEMBL14160818 0.62 P2RX4 (1.00) P2RX4ALDH1A1MAPTSMN1; SMN2MAPK1
SCHEMBL17969634 0.61 CYP19A1 (0.45) P2RX4ALDH1A1MAPTSMN1; SMN2MAPK1
SCHEMBL8985073 0.61 GSK3B (0.67) P2RX4ALDH1A1MAPTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8133913-B2 Substituted indeno [1,2-b]indole derivatives as novel inhibitors of protein kinase CK2 and their use as tumor therapeutic agents, cytostatics and diagnostic aids Heinrich-Heine Universitat Dusseldof (DE) 2012-03-13 — — US disclosed
US-20100056599-A1 SUBSTITUTED INDENO[1,2-B]INDOLE DERIVATIVES AS NOVEL INHIBITORS OF PROTEIN KINASE CK2 AND THEIR USE AS TUMOR THERAPEUTIC AGENTS, CYTOSTATICS AND DIAGNOSTIC AIDS HEINRICH-HEINE UNIVERSITAT DUSSELDORF (DE) 2010-03-04 — — US disclosed
EP-2079691-A1 SUBSTITUTED INDENO[1,2-B]INDOLE DERIVATIVES AS NOVEL INHIBITORS OF PROTEIN KINASE CK2 AND THEIR USE AS TUMOUR THERAPEUTIC AGENTS, CYTOSTATICS AND DIAGNOSTIC AIDS Heinrich-Heine-Universität Düsseldorf (DE) 2009-07-22 — — EP disclosed
WO-2008040547-A1 SUBSTITUTED INDENO[1,2-B]INDOLE DERIVATIVES AS NOVEL INHIBITORS OF PROTEIN KINASE CK2 AND THEIR USE AS TUMOUR THERAPEUTIC AGENTS, CYTOSTATICS AND DIAGNOSTIC AIDS HEINRICH-HEINE UNIVERSITÄT DÜSSELDORF (DE) 2008-04-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056599-A1 SUBSTITUTED INDENO[1,2-B]INDOLE DERIVATIVES AS NOVEL INHIBITORS OF PROTEIN KINASE CK2 AND THEIR USE AS TUMOR THERAPEUTIC AGENTS, CYTOSTATICS AND DIAGNOSTIC AIDS CDK2, CSNK1A1, CDK1 ABCG2 921/4885CSNK2A2 9/4885CSNK2B 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback